Ann M. Hanly - 22 Feb 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Technology Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 22 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Feb 2022, 20:33:28 UTC
Previous filing: 01 Dec 2021
Next filing: 31 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+53,500	+175%	$0.000000	84,100	22 Feb 2022	Direct	F1
holding	VIR	Common Stock						12	22 Feb 2022	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+47,000		$0.000000	47,000	22 Feb 2022	Common Stock	47,000	$29.48	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
F3	25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.